butyl 4-[(2,4-diaminopyrimidin-5-yl)methyl]-2,6-dimethoxybenzoate
![butyl 4-[(2,4-diaminopyrimidin-5-yl)methyl]-2,6-dimethoxybenzoate Structure](https://image.chemsrc.com/caspic/441/55687-47-3.png)
butyl 4-[(2,4-diaminopyrimidin-5-yl)methyl]-2,6-dimethoxybenzoate structure
|
Common Name | butyl 4-[(2,4-diaminopyrimidin-5-yl)methyl]-2,6-dimethoxybenzoate | ||
|---|---|---|---|---|
| CAS Number | 55687-47-3 | Molecular Weight | 360.40800 | |
| Density | 1.22g/cm3 | Boiling Point | 612.8ºC at 760 mmHg | |
| Molecular Formula | C18H24N4O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 324.4ºC | |
| Name | butyl 4-[(2,4-diaminopyrimidin-5-yl)methyl]-2,6-dimethoxybenzoate |
|---|
| Density | 1.22g/cm3 |
|---|---|
| Boiling Point | 612.8ºC at 760 mmHg |
| Molecular Formula | C18H24N4O4 |
| Molecular Weight | 360.40800 |
| Flash Point | 324.4ºC |
| Exact Mass | 360.18000 |
| PSA | 124.04000 |
| LogP | 2.06610 |
| Index of Refraction | 1.587 |
| InChIKey | NOWKJMQWBNFXIP-UHFFFAOYSA-N |
| SMILES | CCCCOC(=O)c1c(OC)cc(Cc2cnc(N)nc2N)cc1OC |
| HS Code | 2933599090 |
|---|
|
~62%
butyl 4-[(2,4-d... CAS#:55687-47-3 |
| Literature: Kompis; Then; Boehni; et al. European Journal of Medicinal Chemistry, 1980 , vol. 15, # 1 p. 17 - 22 |
|
~%
butyl 4-[(2,4-d... CAS#:55687-47-3 |
| Literature: Hoffmann-La Roche Inc. Patent: US3931181 A1, 1976 ; |
|
~%
butyl 4-[(2,4-d... CAS#:55687-47-3 |
| Literature: Kompis; Then; Boehni; et al. European Journal of Medicinal Chemistry, 1980 , vol. 15, # 1 p. 17 - 22 |
|
~%
butyl 4-[(2,4-d... CAS#:55687-47-3 |
| Literature: Kompis; Then; Boehni; et al. European Journal of Medicinal Chemistry, 1980 , vol. 15, # 1 p. 17 - 22 |
|
~%
butyl 4-[(2,4-d... CAS#:55687-47-3 |
| Literature: Kompis; Then; Boehni; et al. European Journal of Medicinal Chemistry, 1980 , vol. 15, # 1 p. 17 - 22 |
![methyl 4-[(2,4-diaminopyrimidin-5-yl)methyl]-2,6-dimethoxybenzoate structure](https://image.chemsrc.com/caspic/217/55687-40-6.png)
| HS Code | 2933599090 |
|---|---|
| Summary | 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |